CRP gene polymorphisms in a series of biopsy-proven GCA and matched controls.
| CRP Polymorphisms | GCA Patients, n (%) | Controls, n (%) | p | OR (95% CI) |
|---|---|---|---|---|
| rs1417938 | n = 116 | n = 192 | ||
| A/A | 6 (5.2) | 15 (7.8) | 0.37 | 0.64 (0.22–1.84) |
| A/T | 56 (48.3) | 68 (35.4) | 0.03 | 1.70 (1.04–2.80) |
| T/T | 54 (46.6) | 109 (56.8) | 0.08 | 0.66 (0.41–1.08) |
| A | 68 (29.3) | 98 (25.5) | 0.30 | 1.21 (0.83–1.77) |
| T | 164 (70.7) | 286 (74.5) | 0.30 | 0.83 (0.57–1.21) |
| rs1800947 | n = 120 | n = 224 | ||
| C/C | 100 (83.3) | 189 (84.4) | 0.80 | 0.93 (0.49–1.76) |
| C/G | 19 (15.8) | 32 (14.3) | 0.70 | 1.13 (0.58–2.18) |
| G/G | 1 (0.8) | 3 (1.3) | 0.56 | 0.62 (0.02–6.75) |
| C | 219 (91.3) | 410 (91.5) | 0.90 | 0.97 (0.54–1.75) |
| G | 21 (8.8) | 38 (8.5) | 0.90 | 1.03 (0.57–1.87) |
| rs1205 | n = 118 | n = 222 | ||
| C/C | 41 (34.7) | 95 (42.8) | 0.15 | 0.71 (0.44–1.16) |
| C/T | 66 (55.9) | 94 (42.3) | 0.02 | 1.73 (1.07–2.78) |
| T/T | 11 (9.3) | 33 (14.9) | 0.15 | 0.59 (0.27–1.27) |
| C | 148 (62.7) | 284 (64.0) | 0.75 | 0.95 (0.67–1.33) |
| T | 88 (37.3) | 160 (36.0) | 0.75 | 1.06 (0.75–1.48) |
| rs3093059 | n = 123 | n = 234 | ||
| C/C | 0 (0) | 3 (1.3) | 0.21 | 0.47 (0.29–1.03) |
| C/T | 13 (10.6) | 39 (16.7) | 0.12 | 0.62 (0.32–1.20) |
| T/T | 110 (89.4) | 192 (82.1) | 0.07 | 1.77 (0.92–3.40) |
| C | 13 (5.3) | 45 (9.6) | 0.04 | 0.55 (0.29–1.03) |
| T | 233 (94.7) | 423 (90.4) | 0.04 | 1.81 (0.97–3.39) |
CRP: C-reactive protein; GCA: giant cell arteritis.